Neuronetics Engaging at a Prominent Healthcare Conference
MALVERN, Pa. — Neuronetics, Inc., (NASDAQ: STIM) has exciting news to share as they prepare to take part in a significant healthcare event aimed at fostering discourse on mental health advancements. The conference, renowned for bringing together industry leaders and innovators, provides an excellent platform for showcasing the company's dedication to improving patient outcomes.
The Company’s Mission in Mental Health Treatment
Neuronetics stands at the forefront of mental health, focusing on the intersection of neuroscience and therapy. With a vision of delivering innovative solutions, the company believes that mental wellness is just as crucial as physical health. They aim to empower patients by expanding treatment options with advanced therapies designed to enhance living quality, especially for those who have not found relief through traditional medications.
Innovative Treatments Provided
Central to Neuronetics’ offerings is the NeuroStar Advanced Therapy. This unique, non-invasive treatment option is tailored for individuals dealing with Major Depressive Disorder (MDD). Significant results make it a leading choice, with over 7.4 million treatments administered. Backed by extensive clinical research, this therapy boasts the largest clinical data set for any transcranial magnetic stimulation (TMS) treatment system available, underscoring its effectiveness.
Participation in Industry Discussions
The management team of Neuronetics will engage in a fireside chat during the conference, which is set for the afternoon of December 4, 2025. This interactive format will allow attendees to understand the company’s philosophy, advancements in treatment options, and patient care strategies.
Commitment to Extensive Outreach
Additionally, Neuronetics collaborates with Greenbrook TMS Inc., which operates numerous treatment centers across the country. These centers enhance access to the NeuroStar Advanced Therapy while also offering SPRAVATO® (esketamine) for treatment-resistant depression. Collectively, they have provided over 1.8 million treatments, positively impacting the lives of more than 55,000 individuals facing depression.
Regulatory Compliance and Safety
The NeuroStar Advanced Therapy System is FDA-cleared, ensuring safety and effectiveness. It’s approved for adult patients diagnosed with MDD and acts as an adjunctive treatment for anxiety among patients experiencing both MDD and anxiety symptoms. Furthermore, it extends its application to adolescents aged 15-21 as a first-line adjunct for MDD treatment, highlighting its broad reach in the mental health landscape.
Contact Information for Investors
As Neuronetics gears up for this vital engagement, they encourage stakeholders and potential investors to reach out with inquiries. For investor-related questions, they can contact Mike Vallie or Mark Klausner at ICR Healthcare, by calling 443-213-0499 or emailing ir@neuronetics.com.
Frequently Asked Questions
What is the primary focus of Neuronetics?
Neuronetics primarily focuses on providing innovative neurohealth therapies to improve mental well-being.
When is Neuronetics participating in the healthcare conference?
The participation is scheduled for December 4, 2025, with details available in the conference portal.
What treatment does NeuroStar Advanced Therapy offer?
NeuroStar Advanced Therapy offers non-invasive treatments primarily for Major Depressive Disorder.
How does Neuronetics support patients with depression?
They provide valuable resources through their treatment centers and innovative therapies aimed at improving mental health outcomes.
Who can I contact for more information about Neuronetics?
For investor inquiries, individuals can reach out to Mike Vallie or Mark Klausner at ICR Healthcare.
